efficacy and safety of Biretrix Tri-Active Spray with Doxycycline in patients with mild to moderate truncal acne

The study of efficacy and safety of Biretrix Tri-Active Spray with Doxycycline versus Vitamin A acid lotion 0.025% with Doxycycline in patients with mild to moderate truncal acne, a randomized control trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240528001

Enrollment

Registered

2024-05-28

Start date

2022-06-11

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

truncal acne truncal acne Biretrix tri active spray sebum pigment quality of life

Interventions

Biretrix tri active spray,0.025% vitamin A lotion

Experimental Other,Active Comparator Drug

Biretrix tri active spray,vitamin A lotion

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.individuals aging 18-45 years old 2.mild to moderate truncal acne (assessed with PGA) 3. not allergic to Biretrix tri active spray or its compositions

Exclusion criteria

Exclusion criteria: 1. syndromic acne 2.on oral contraceptive pills or medications that affect acne condition 3.have other active skin conditions 4. pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
acne count at 3 months after intervention lesion count	—

Secondary

Measure	Time frame
ratio of patient achieving clear/almost clear of acne lesion 3 months lesion count,sebum reduction 3 months sebumeter ,pigment reduction 3 months colorimeter, antera,quality of life and satisfaction 3 months DLQI, patient satisfaction scale,adverse effects 3 months questionnaire	—

Countries

Thailand

Contacts

Public Contactchanat kumtornrut

faculty of medicine, chulalongkorn university

chanat_1@yahoo.com022564253

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026